Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: A contemporary meta-analysis of randomised controlled trials

Heart

Volumn 96, Issue 20, 2010, Pages 1622-1626

  Zhao, Yun Tao ^a   Weng, Cui Lian ^b   Chen, Mu Lei ^a   Li, Kui Bao ^a   Ge, Yong Gui ^a   Lin, Xiang Min ^a   Zhao, Wen Shu ^a   Chen, Jin ^a   Zhang, Lin ^a   Yin, Jun Xiang ^c   Yang, Xin Chun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c Ministry of Science and Technology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; POTASSIUM;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REPERFUSION; SYSTEMATIC REVIEW;

AGED; CARDIOPLEGIC SOLUTIONS; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; FEMALE; GLUCOSE; HUMANS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POTASSIUM; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78049311248     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.194563     Document Type: Article

References (36)

1. Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction: a preliminary clinical report. Am J Cardiol 1962;9:166-81.
2. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
3. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998;98:2227-34.
4. Ceremuzynski L, Budaj A, Czepiel A, et al. Low-dose glucose-insulin- potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999;13:191-200.
5. van der Horst IC, Zijlstra F, van 't Hof AW, et al. Glucose-insulin- potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003;42:784-91.
6. Pache J, Kastrati A, Mehilli J, et al. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 2004;148:e3.
7. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-46.
8. Krljanac G, Vasiljevic Z, Radovanovic M, et al. Effects of glucose-insulin-potassium infusion on ST-elevation myocardial infarction in patients treated with thrombolytic therapy. Am J Cardiol 2005;96:1053-8. (Pubitemid 41416594)
9. Rasoul S, Ottervanger JP, Timmer JR, et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-Insulin-Potassium study II. Int J Cardiol 2007;122:52-5.
10. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007;298:2399-405.
11. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
12. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61.
13. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006;29:765-70.
14. Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J 2005;26:956-9.
15. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610-19. (Pubitemid 351440650)
16. Kloner RA, Nesto RW. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation 2008;117:2523-33.
17. Opie LH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation 2008;117:2172-7.
18. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-900.
19. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
20. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-60. (Pubitemid 29436453)
21. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
23. Opie LH. Glucose-insulin-potassium therapy in patients with STEMI. JAMA 2008;299:2385-6; author reply 7-8.
24. Timmer JR, Svilaas T, Ottervanger JP, et al. Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol 2006;47:1730-1.
25. Opie LH, Tansey M, Kennelly BM. Proposed metabolic vicious circle in patients with large myocardial infarcts and high plasma-free-fatty-acid concentrations. Lancet 1977;2:890-2.
26. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117:1018-27.
27. Goyal A, Mahaffey KW, Garg J, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 2006;27:1289-97.
28. De Leiris J, Opie LH, Lubbe WF. Effects of free fatty acid and enzyme release in experimental glucose on myocardial infarction. Nature 1975;253:746-7.
29. Jonassen AK, Sack MN, Mjos OD, et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89:1191-8.
30. Galinanes M, Fowler AG. Role of clinical pathologies in myocardial injury following ischaemia and reperfusion. Cardiovasc Res 2004;61:512-21.
31. Vinten-Johansen J, Zhao ZQ, Zatta AJ, et al. Postconditioning: a new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol 2005;100:295-310. (Pubitemid 40974080)
32. Ceriello A. Acute hyperglycaemia: a 'new' risk factor during myocardial infarction. Eur Heart J 2005;26:328-31.
33. Timmer JR, Ottervanger JP, de Boer MJ, et al. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005;45:999-1002.
34. Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004;109:849-54.
35. Marfella R, Di Filippo C, Portoghese M, et al. Acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol 2009;53:1425-36.
36. Flather MD, Farkouh ME, Pogue JM, et al. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials 1997;18:568-79.